Earnings
Home›Earnings›Previews›Novartis’ remibrutinib Phase 3 results point to major…
Novartis’ remibrutinib Phase 3 results point to major MS sales upside
Bank of America estimates remibrutinib could reach about $3.0 billion in peak annual sales for multiple sclerosis alone, with potentially more than $10 billion across all indications.
Novartis has received encouraging Phase 3 data for remibrutinib, a treatment being studied for relapsing multiple sclerosis, results that could open a sizable commercial opportunity for the company as it works through regulatory steps, according to Yahoo Finance. The REMODEL-1 and REMODEL-2 trials reported that remibrutinib reduced relapse activity and met the trials' primary endpoints. Yahoo Finance also notes the program showed reductions in inflammatory brain lesions versus an active comparator and reported a favorable safety profile. Bank of America estimates remibrutinib could generate about $3 billion in peak annual sales in multiple sclerosis alone, and potentially more than $10 billion across all indications. The article ties the potential growth to an MS therapeutics market projected to reach roughly $38.6 billion by 2030, growing at a 5.9% compound annual rate. Novartis’ existing MS franchise centers on Kesimpta, which the article says generated about $1.42 billion in second-quarter sales, up 32% year over year, helped by strong demand and favorable payer access. Still, Yahoo Finance highlights risks including the possibility that maintaining robust Kesimpta sales could get harder as the drug matures and competition intensifies.